Association of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapy
نویسندگان
چکیده
منابع مشابه
the study of aaag repeat polymorphism in promoter of errg gene and its association with the risk of breast cancer in isfahan region
چکیده: سرطان پستان دومین عامل مرگ مرتبط با سرطان در خانم ها است. از آنجا که سرطان پستان یک تومور وابسته به هورمون است، می تواند توسط وضعیت هورمون های استروئیدی شامل استروژن و پروژسترون تنظیم شود. استروژن نقش مهمی در توسعه و پیشرفت سرطان پستان ایفا می کند و تاثیر خود را روی بیان ژن های هدف از طریق گیرنده های استروژن اعمال می کند. اما گروه دیگری از گیرنده های هسته ای به نام گیرنده های مرتبط به ا...
15 صفحه اولNontraditional serum lipid variables and recurrent stroke risk.
BACKGROUND AND PURPOSE Expert consensus guidelines recommend low-density lipoprotein cholesterol as the primary serum lipid target for recurrent stroke risk reduction. However, mounting evidence suggests that other lipid parameters might be additional therapeutic targets or at least also predict cardiovascular risk. Little is known about the effects of nontraditional lipid variables on recurren...
متن کاملLipid-modifying therapy in the elderly
Cardiovascular disease (CVD) mortality and morbidity increases with increasing age, largely as a result of increased lifetime exposure as well as increased prevalence of CVD risk factors. Hospitalization for CVD increases by a factor of over 18× for those aged 85+ years versus those aged <30 years. In spite of this, life expectancy continues to increase, and in Australia for people reaching the...
متن کاملEvolving targets for lipid-modifying therapy
The pathogenesis and progression of atherosclerosis are integrally connected to the concentration and function of lipoproteins in various classes. This review examines existing and emerging approaches to modify low-density lipoprotein and lipoprotein (a), triglyceride-rich lipoproteins, and high-density lipoproteins, emphasizing approaches that have progressed to clinical evaluation. Targeting ...
متن کاملLipid lowering and recurrent stroke: another stroke paradox?
The meta-analysis of over 90 000 patients included in statin trials shows a significant 21% reduction of stroke with no heterogeneity between trials and no increase in haemorrhagic stroke. Because the link between total cholesterol and incident stroke has never been clearly established in epidemiological studies, it is surprising to see, in the meta-analysis, that the larger the between-group L...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Atherosclerosis and Thrombosis
سال: 2020
ISSN: 1340-3478,1880-3873
DOI: 10.5551/jat.49304